EGFR pharmacogenomics: the story continues to mutate and evolve.
Desai
Apurva A
AA
Section of Hematology and Oncology, University of Chicago, Illinois 60637, USA. adesai@medicine.bsd.uchicago.edu
Ratain
Mark J
MJ
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics; D017326:Clinical Trials, Phase III as Topic; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics; D009154:Mutation; D010597:Pharmacogenetics / Q000639:trends*; D011505:Protein-Tyrosine Kinases / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
D011799:Quinazolines; C118029:CL 387785; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D000077156:Gefitinib